Search

Your search keyword '"Morphine Derivatives blood"' showing total 33 results

Search Constraints

Start Over You searched for: Descriptor "Morphine Derivatives blood" Remove constraint Descriptor: "Morphine Derivatives blood" Topic pain Remove constraint Topic: pain
33 results on '"Morphine Derivatives blood"'

Search Results

1. A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer Patients.

2. Serum concentrations of opioids when comparing two switching strategies to methadone for cancer pain.

3. Relationship between plasma concentrations of morphine and its metabolites and pain in cancer patients.

4. Pharmacokinetic and pharmacodynamic study of morphine and morphine 6-glucuronide after oral and intravenous administration of morphine in children with cancer.

5. Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: an open-label trial.

6. Pharmacological consequences of long-term morphine treatment in patients with cancer and chronic non-malignant pain.

7. The bioavailability of morphine applied topically to cutaneous ulcers.

8. The oral-to-intravenous equianalgesic ratio of morphine based on plasma concentrations of morphine and metabolites in advanced cancer patients receiving chronic morphine treatment.

9. Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients.

10. Influences on serum concentrations of morphine, M6G and M3G during routine clinical drug monitoring: a prospective survey in 300 adult cancer patients.

11. Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain.

12. Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers.

13. Contribution of morphine-6-glucuronide to antinociception following intravenous administration of morphine to healthy volunteers.

14. Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine.

15. Changing M3G/M6G ratios and pharmacodynamics in a cancer patient during long-term morphine treatment.

16. Antinociceptive effects of morphine-6-glucuronide in homozygous MDR1a P-glycoprotein knockout and in wildtype mice in the hotplate test.

17. Morphine or oxycodone in cancer pain?

18. Population pharmacokinetics of oral morphine and its glucuronides in children receiving morphine as immediate-release liquid or sustained-release tablets for cancer pain.

19. Pharmacokinetics of morphine and its glucuronides following intravenous administration of morphine in patients undergoing continuous ambulatory peritoneal dialysis.

20. Cerebrospinal fluid and plasma concentrations of morphine, morphine-3-glucuronide, and morphine-6-glucuronide in patients before and after initiation of intracerebroventricular morphine for cancer pain management.

21. Lack of analgesic activity of morphine-6-glucuronide after short-term intravenous administration in healthy volunteers.

22. Morphine and morphine-6-glucuronide plasma concentrations and effect in cancer pain.

23. Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients.

24. Morphine and morphine-glucuronide concentrations in plasma and CSF during long-term administration of oral morphine.

25. Concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide in serum and cerebrospinal fluid following morphine administration to patients with morphine-resistant pain.

26. The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function.

27. Pharmacokinetics and efficacy of rectal versus oral sustained-release morphine in cancer patients.

28. Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure.

29. Chronic morphine therapy for cancer pain: plasma and cerebrospinal fluid morphine and morphine-6-glucuronide concentrations.

30. Chronic nausea and morphine-6-glucuronide.

31. Plasma morphine and morphine-6-glucuronide patterns in cancer patients after oral, subcutaneous, sublabial and rectal short-term administration.

32. Oral morphine in cancer pain: influences on morphine and metabolite concentration.

33. The pharmacokinetics of heroin in patients with chronic pain.

Catalog

Books, media, physical & digital resources